From the Division of Molecular Medicine, Bose Institute, Kolkata, West Bengal 700 054 India and.
Department of Urology, Nil Ratan Sircar Medical College and Hospital, Kolkata, West Bengal 700 014 India.
J Biol Chem. 2019 Jan 18;294(3):1005-1018. doi: 10.1074/jbc.RA118.004485. Epub 2018 Nov 21.
GM2-synthase produces sialic acid-containing glycosphingolipids called gangliosides, and its mRNA overexpression and the gangliosides it generates are linked to tumor progression, migration, and suppression of tumor-specific host immune responses. However, the mechanism underlying GM2-synthase de-repression in renal cell carcinoma (RCC) is poorly understood. Here, we demonstrate that higher GM2-synthase mRNA expression levels in various cancer cells and in human RCC tumors correlate with higher histone acetylation levels (H3K9, H3K14, or both) at region +38/+187 relative to the transcription start site (TSS) of the GM2-synthase gene than in normal kidney epithelial (NKE) cells or healthy adjacent tissues. An increase in GM2-synthase mRNA expression in cells treated with a histone deacetylase (HDAC) inhibitor was accompanied by increased histone acetylation levels at this promoter region. DNA methylation around the TSS was absent in both RCC cell lines and NKE cells. Of note, both the transcription factor Sp1 and corepressor HDAC1 associated with the +38/+187 region when the GM2-synthase gene was repressed in NKE and tumor-adjacent tissues, indicating plausible site-specific repressive roles of HDAC1 and Sp1 in GM2-synthase mRNA expression. Site-directed mutagenesis of the Sp1-binding site within the +38/+187 region relieved repressed luciferase activity of this region by limiting HDAC1 recruitment. Moreover, Sp1 or HDAC1 knock down increased GM2-synthase transcription, and butyrate-mediated activation of GM2-synthase mRNA expression in SK-RC-45 cells was accompanied by Sp1 and HDAC1 loss from the +38/+187 region. Taken together, we have identified an epigenetic mechanism for the de-repression of the GM2-synthase gene in RCC.
GM2 合成酶产生含有唾液酸的糖脂神经节苷脂,其 mRNA 过表达及其产生的神经节苷脂与肿瘤进展、迁移以及抑制肿瘤特异性宿主免疫反应有关。然而,肾细胞癌 (RCC) 中 GM2 合成酶去抑制的机制尚不清楚。在这里,我们证明各种癌细胞和人 RCC 肿瘤中 GM2 合成酶 mRNA 表达水平较高与相对于 GM2 合成酶基因的转录起始位点 (TSS) 在+38/+187 处的组蛋白乙酰化水平 (H3K9、H3K14 或两者) 较高有关,高于正常肾上皮 (NKE) 细胞或健康相邻组织。用组蛋白去乙酰化酶 (HDAC) 抑制剂处理的细胞中 GM2 合成酶 mRNA 表达增加伴随着该启动子区域组蛋白乙酰化水平的增加。在 RCC 细胞系和 NKE 细胞中,TSS 周围的 DNA 甲基化均不存在。值得注意的是,当 GM2 合成酶基因在 NKE 和肿瘤相邻组织中被抑制时,转录因子 Sp1 和核心抑制因子 HDAC1 都与+38/+187 区域结合,表明 HDAC1 和 Sp1 在 GM2 合成酶 mRNA 表达中具有可能的特定位点抑制作用。在+38/+187 区域内 Sp1 结合位点的定点突变通过限制 HDAC1 的募集来缓解该区域受抑制的荧光素酶活性。此外,Sp1 或 HDAC1 的敲低增加了 GM2 合成酶的转录,而丁酸介导的 SK-RC-45 细胞中 GM2 合成酶 mRNA 表达的激活伴随着+38/+187 区域中 Sp1 和 HDAC1 的丢失。总之,我们已经确定了 RCC 中 GM2 合成酶基因去抑制的表观遗传机制。